key: cord-0013547-qyk9biex authors: Siddiqui, Shahid Akhtar; Singh, Mukesh Vir title: Therapeutic Clowning in Pediatric Practice: A Novel Concept to Think About in India date: 2020-09-05 journal: Indian Pediatr DOI: 10.1007/s13312-020-2015-3 sha: bd332d13688a8622ae01e49f60ffa7d96555c488 doc_id: 13547 cord_uid: qyk9biex nan We read the very timely article by Bhat, et al. [1] providing valuable insights into clinical epidemiology of multisystem inflammatory syndrome in children (MIS-C). We comment on the recent evidence to complement the information provided. Recent clinical guidelines by American College of Rheumatology (ACR) elaborate on the most appropriate diagnostic and therapeutic steps for MIS-C at the present time, advising inflammatory markers and cytokine panel testing [2] . There is noteworthy discordance in interleukin levels of IL-1, IL-6 and IL-10 among patients with Kawasaki disease (KD) vs MIS-C [3] . While IL-1 is the main mediator of coronary artery inflammation in KD, inflammatory process in MIS-C is predominantly driven by IL-6 and IL-10, which may play a role in the myocardial dysfunction and higher severity of the 2019-nCoV infection [4] . We concur with the authors that the role for specific cytokine blockade including use of biologics in MIS-C is still lacking. The ACR guidelines advice immunomodulatory therapy for all severe/critical MIS-C patients with shock, significant respiratory distress, neurologic changes, dehydration, or features of KD. IVIG and glucocorticoid remain first line agents either alone or in combination. Anakinra is safe in severe infections among children with hyper-inflammatory syndromes. Although tocilizumab is effective in reducing mortality and ICU admission in patients with severe COVID-19 pneumonia [2] , the clinical evidence is insufficient regarding its efficacy and safety for COVID-19 because of concerns regarding risk of secondary bacterial and fungal infections [5] . Aspirin (3-5 mg/kg/day) should be used in patients with MIS-C and KD-like features and/or thrombocytosis and continued until normali-zation of platelet count and confirmed normal coronary arteries at ≥4 weeks after diagnosis. Anticoagulation with enoxaparin should be added in patients with coronary artery aneurysm and Z score ≥10.0 or an ejection fraction (EF) <35% [2] , but despite benefits, strategy based evidence is required due to high risk of hemorrhagic events or complications. With the availability of these guidelines a standardized treatment plan for MIS-C involving multidisciplinary care Therapeutic clowning in paediatric practice Medical clowning: even adults deserve a dream Hospital clowning: A paediatrician's view Clowning as a supportive measure in paediatrics -A survey of clowns, parents and nursing staff Humor and laughter may influence health: III. Laughter and health outcomes